Pemvidutide: Molecular Structure
Chemical properties, amino acid sequence, and structural analysis
📌TL;DR
- •Molecular formula: Proprietary (not publicly disclosed)
- •Molecular weight: 3873.35 Da
- •Half-life: Approximately 100 hours (supports once-weekly dosing)
Amino Acid Sequence
68 amino acids
Formula
Proprietary (not publicly disclosed)
Molecular Weight
3873.35 Da
Half-Life
Approximately 100 hours (supports once-weekly dosing)
Molecular Structure#
Pemvidutide is a 29-amino acid synthetic peptide that functions as a balanced dual GLP-1/glucagon receptor agonist. The peptide backbone is designed for approximately 1:1 GLP-1 and glucagon receptor potency. A C18 fatty diacid moiety is conjugated to the peptide, enabling non-covalent albumin binding that extends the plasma half-life to support once-weekly dosing.
Key Structural Features#
| Feature | Description |
|---|---|
| Peptide length | 29 amino acids |
| Receptor targets | GLP-1R and GCGR (balanced 1:1) |
| Lipid modification | C18 fatty diacid |
| Half-life extension | Albumin binding via fatty acid |
| Proprietary element | EuPort domain technology |
EuPort Domain Technology#
Pemvidutide incorporates Altimmune's EuPort domain, a proprietary structural feature designed to improve gastrointestinal tolerability. This domain is thought to modulate receptor engagement kinetics, potentially contributing to the reduced nausea and vomiting rates observed compared to some GLP-1-only agonists.
Pharmacokinetic Properties#
| Parameter | Value |
|---|---|
| Half-life | Approximately 100 hours |
| Administration | Once-weekly subcutaneous injection |
| Dose titration | Not required |
| Steady state | Reached within several weeks |
Stability#
As a peptide with lipid modification, pemvidutide requires refrigerated storage. Full stability data have not been publicly disclosed.
Molecular Context#
Pemvidutide belongs to the Metabolic category of research peptides. The molecular properties of Pemvidutide determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.
Structural Overview#
Pemvidutide is characterized as: Pemvidutide is a 29-amino acid peptide engineered for balanced GLP-1 and glucagon receptor co-agonism. It incorporates a C18 fatty diacid side chain that binds albumin, extending the half-life to enable once-weekly subcutaneous administration. The molecule includes Altimmune's proprietary EuPort domain technology designed to improve tolerability and reduce gastrointestinal side effects..
Amino Acid Sequence Details#
The amino acid sequence of Pemvidutide is: Not publicly disclosed (29-amino acid peptide with C18 fatty diacid). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.
Pharmacokinetic Profile#
Half-Life: Approximately 100 hours (supports once-weekly dosing)
The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.
Related Reading#
Frequently Asked Questions About Pemvidutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer